Celularity Inc

For the period ended Mar 31, 2024. Filed Oct 16, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed Oct 16, 2024

CELU$0.71-6.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

	Three Months Ended March 31,
2024 · 2023
Cash flow from operating activities:
Net loss		$(22,013)		$(64,017)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization		2,156		2,363
Non cash lease expense		45		(19)
Provision for doubtful accounts		201		611
Provision for inventory obsolescence		(45)		-
Change in fair value of warrant liabilities		8,875		(1,735)
Goodwill impairment		-		29,633
Stock-based compensation expense		2,966		3,988
Change in fair value of contingent consideration		-		(18,932)
Acquired in-process research and development		-		3,000
Issuance of common stock for stem-cells to be used in research and development		-		1,000
Issuance of common stock to Palantir as consideration for settlement agreement		50		-
Issuance of common stock relating to Yorkville for debt extension and SEPA commitment fee		317		-
Change in fair value of contingent stock consideration		-		(110)
Loss on extinguishment of debt		3,908		-
Change in fair value of debt		(81)		1,280
Non cash interest expense		1,148		-
Other, net		181		272
Changes in assets and liabilities:		-
Accounts receivable		(3,924)		791
Inventory		3,181		(1,813)
Prepaid expenses and other assets		294		1,463
Accounts payable		(1,172)		2,730
Accrued expenses and other liabilities		1,171		729
Accrued R&D software		(1,800)		23,675
Lease liabilities - operating		88		64
Deferred revenue		51		32
Net cash used in operating activities		(4,403)		(14,995)
Cash flow from investing activities:
Capital expenditures		(39)		(209)
Purchase of acquired in-process research and development		-		(3,000)
Net cash used in investing activities		(39)		(3,209)
Cash flow from financing activities:
Proceeds from warrants and short-term debt - related parties		15,000		4,994
Proceeds from the exercise of stock options		-		300
Repayments of short-term debt - unaffiliated		(17,374)		(1,618)
Proceeds from issuance of short-term debt - unaffiliated		2,993		-
Payment of SEPA commitment fee		(25)		-
Repayments of short-term debt - related parties		(10)		-
Proceeds from PIPE Offering, net of offering costs		6,000		9,000
Proceeds from the sale of common stock in ATM offering		-		136
Tax withholding on vesting of restricted stock units		(357)		(53)
Net cash provided by financing activities		6,227		12,759
Net increase (decrease) in cash, cash equivalents and restricted cash		1,785		(5,445)
Cash, cash equivalents and restricted cash at beginning of period		10,163		28,802
Cash, cash equivalents and restricted cash at end of period		$11,948		$23,357
Supplemental disclosure of cash flow information:
Cash paid for interest	$	-		$251
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses		$(11)		$(697)
Modification of C.V. Starr warrants in connection with forbearance		$51	$	-
Issuance of RWI warrants in connection with forbearance		$1,223	$	-
Issuance of warrants on senior secured bridge loan	$	-		$274
PIPE related offering costs included in accrued expenses	$	-		$(69)
Common stock issued for short-term debt conversion	$	-		$3,510

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.